Daily ReportNov 4, 2026
Sepsis, November 4 edition
We read 30 papers and selected 3.
Summary
Today’s most impactful sepsis research spans a mechanistically precise immunometabolic intervention, a systematic evaluation of neutrophil extracellular trap modulation, and a large real-world comparison of glucose-lowering therapies. Together, these studies connect molecular pathophysiology with translational therapy development and clinically relevant prevention signals, while emphasizing the need for prospective validation.
Research Themes
- Immunometabolic and redox mechanisms of sepsis-associated organ injury
- Neutrophil extracellular trap modulation as a therapeutic strategy
- Real-world pharmacologic prevention of sepsis in high-risk patients
Selected Articles
1. Itaconate alleviates sepsis-induced acute lung injury by suppressing Peroxiredoxin 1 dimerization through covalent alkylates at Cys173.
Using clinical data, macrophage experiments, chemical proteomics, mutagenesis, and a murine cecal ligation and puncture model, the study identified an ACOD1–itaconate pathway that restrains PRDX1-driven inflammation. Itaconate covalently alkylated PRDX1 at Cys173, prevented intermolecular disulfide-linked dimerization and secretion, and reduced downstream TLR4, MAPK, and NF-κB signaling. The C173S mutation abolished the therapeutic effect of 4-octyl itaconate, providing target-level mechanistic validation.
Impact: This study provides a specific covalent biochemical mechanism linking immunometabolism, redox biology, and extracellular danger signaling in sepsis-associated lung injury. The Cys173-dependent mechanism creates a defined therapeutic target rather than proposing nonspecific anti-inflammatory suppression.
Clinical Implications: The findings support development of PRDX1 dimerization inhibitors or itaconate-based interventions for sepsis-associated lung injury. Clinical translation will require pharmacokinetic, safety, infection-control, and efficacy studies in more clinically representative models before human trials.
Key Findings
- Elevated PRDX1 expression was strongly associated with sepsis mortality in clinical datasets.
- Acod1 deficiency worsened murine sepsis-associated lung injury, whereas 4-octyl itaconate reduced lung injury and cytokine storm.
- Itaconate alkylated PRDX1 at Cys173, blocked disulfide-linked dimerization and secretion, and suppressed TLR4-MAPK-NF-κB signaling.
- The PRDX1-C173S mutation abolished the inhibitory effect of 4-octyl itaconate.
Methodological Strengths
- Integrated clinical association, in vitro cellular, chemical proteomic, mutational, and in vivo sepsis-model evidence.
- The Cys173 loss-of-function experiment provided direct target-specific mechanistic validation.
Limitations
- The therapeutic evidence was primarily generated in murine CLP models and cultured macrophages, limiting immediate clinical generalizability.
- The abstract does not establish optimal dosing, treatment timing, long-term safety, or effects on pathogen clearance in humans.
Future Directions: Future studies should test PRDX1-Cys173-directed compounds in multiple infectious sepsis models, define therapeutic windows and pharmacology, assess effects on bacterial clearance and host defense, and evaluate biomarkers that identify patients with PRDX1-driven lung injury.
Sepsis-associated acute lung injury (SALI) is characterized by overwhelming inflammation and oxidative stress, during which damage-associated molecular patterns (DAMPs) exacerbate tissue injury. Peroxiredoxin 1 (PRDX1), a canonical intracellular antioxidant enzyme, paradoxically functions as a pro-inflammatory DAMP after extracellular release. This pathogenic transition depends on PRDX1 dimerization through intermolecular disulfide bonds. However, the endogenous metabolic mechanisms that restrain PRDX1 release remain unclear. Here, we identify the ACOD1-itaconate axis as a critical suppressor of PRDX1-mediated hyperinflammation in SALI.
2. Treating sepsis by targeting neutrophil extracellular traps: a systematic review and meta-analysis.
This PRISMA-based systematic review and random-effects meta-analysis included 33 experimental studies of NETs-targeting interventions in sepsis models. Treatment generally reduced NETs, mortality risk, IL-6, IL-1β, and TNF-α, and was associated with less tissue injury, although tissue-injury outcomes were heterogeneous. The evidence was dominated by lipopolysaccharide endotoxemia rodent models and was limited by small study numbers, publication bias, protocol heterogeneity, and poor reporting.
Impact: This study quantitatively synthesizes a rapidly expanding therapeutic field and identifies a consistent experimental signal while explicitly showing why clinical translation remains premature. Its moderator analysis and conservative interpretation are valuable for prioritizing intervention classes and designing better preclinical studies.
Clinical Implications: NETs modulation should currently be regarded as a preclinical therapeutic strategy rather than routine clinical treatment for sepsis. Future translation should prioritize infection-relevant animal models, standardized NETs measurement, treatment-window optimization, and safety assessment regarding host defense and thrombosis.
Key Findings
- Thirty-three experimental studies were included in the meta-analysis.
- NETs-targeting interventions significantly reduced NETs levels overall, although three studies reported increased NETs after treatment.
- Treatment was associated with lower mortality risk and reduced IL-6, IL-1β, and TNF-α concentrations.
- Tissue injury was reduced but showed considerable heterogeneity, with I² = 68.4%.
- Most evidence came from lipopolysaccharide endotoxemia rodent models, limiting clinical translatability.
Methodological Strengths
- The protocol was prospectively registered with PROSPERO and reported according to PRISMA principles.
- Random-effects modeling with restricted maximum likelihood and prespecified moderators addressed between-study variability.
Limitations
- The included studies were small, heterogeneous, and frequently poorly reported, with evidence of publication bias.
- The evidence base was heavily weighted toward lipopolysaccharide endotoxemia models rather than polymicrobial infection or clinically representative sepsis models.
Future Directions: Future studies should use standardized NETs assays, preregistered protocols, clinically relevant polymicrobial models, sex-balanced designs, and predefined outcomes. Comparative studies should identify which intervention classes preserve antimicrobial host defense while limiting immunothrombosis and organ injury.
BACKGROUND: Sepsis, a leading cause of death worldwide, is characterized by dysregulated host immune responses and multi-organ dysfunction. Neutrophil extracellular traps (NETs) are extracellular fibers from activated neutrophils that contribute to the immune response. However, excessive NETs formation during sepsis may exacerbate inflammation, thrombosis, and tissue injury, potentially affecting sepsis prognosis. We examined whether NETs-modulating interventions are beneficial in experimental sepsis models. METHODS: Following PRISMA guidelines, this review analyzed studies from PubMed and Scopus that reported NETs-targeting therapies and included outcome measures. A meta-analysis of random-effects models using a restricted maximum likelihood estimation was performed with a priori moderators including NETs quantification tier, intervention timing relative to insult, and intervention class.
3. Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
In this active-comparator, new-user cohort using the TriNetX Global Network, 20,074 propensity-matched pairs of patients with COPD and type 2 diabetes were compared. GLP-1 receptor agonist use was associated with lower 1-year risks of sepsis, pneumonia, and all-cause mortality than DPP-4 inhibitor use; the 1-year hazard ratio for sepsis was 0.852 and for mortality was 0.656. Because the study was observational, residual confounding and treatment-selection bias remain possible.
Impact: The study addresses a common high-risk population and identifies a potentially actionable difference between two widely used medication classes. Its large active-comparator new-user design and clinically important outcomes generate a strong hypothesis for randomized trials, although the associations cannot establish causality.
Clinical Implications: For patients with COPD and type 2 diabetes, the findings may support consideration of GLP-1 receptor agonists when otherwise clinically appropriate, particularly in individuals at high infection risk. Treatment decisions should not yet be based on sepsis prevention alone, and prospective randomized evidence is needed.
Key Findings
- Before matching, 21,622 patients initiated GLP-1 receptor agonists and 67,259 initiated DPP-4 inhibitors; 20,074 patients remained in each matched group.
- At 1 year, GLP-1 receptor agonist use was associated with lower sepsis risk than DPP-4 inhibitor use, with HR 0.852 and 95% CI 0.770-0.942.
- At 1 year, pneumonia and all-cause mortality were also lower with GLP-1 receptor agonists, with HRs of 0.729 and 0.656, respectively.
- The association with severe sepsis was not statistically significant, with HR 0.891 and 95% CI 0.770-1.033.
Methodological Strengths
- The active-comparator, new-user design reduced some biases associated with prevalent medication use and inappropriate comparator selection.
- Large-scale propensity score matching achieved balanced measured covariates, with all standardized mean differences below 0.10.
Limitations
- The observational database design cannot establish that GLP-1 receptor agonists caused lower infection or mortality risks.
- Residual confounding, exposure misclassification, unmeasured disease severity, adherence, socioeconomic factors, and healthcare-access differences may remain.
Future Directions: Randomized trials or target-trial emulations should evaluate infection and sepsis outcomes as prespecified endpoints, while mechanistic studies should examine whether anti-inflammatory, metabolic, pulmonary, or weight-related effects mediate the association. Replication in diverse healthcare systems and high-risk subgroups is also needed.
BACKGROUND: Sepsis is a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). Antihyperglycemic agents may influence infection risk through distinct immunometabolic pathways. We compared glucagon-like peptide-1 receptor agonists (GLP-1RAs) with dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with COPD and type 2 diabetes mellitus (T2DM). METHODS: This population-based, active-comparator, new-user cohort study used the TriNetX Global Network. Adults aged 40-100 years with COPD and T2DM who initiated a GLP-1RA or DPP-4i between 2007 and 2019 were included. Propensity score matching (1:1) adjusted for demographics, BMI, HbA1c, COPD severity proxies, comorbidities, and medications.